Alessandra Tedeschi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1784427/publications.pdf

Version: 2024-02-01

72 papers	4,807 citations	257450 24 h-index	114465 63 g-index
72 all docs	72 docs citations	72 times ranked	4105 citing authors

#	Article	IF	Citations
1	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for WaldenstrÃ¶m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology, 2022, 40, 52-62.	1.6	62
2	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Advances, 2022, 6, 1742-1753.	5.2	33
3	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica, 2022, 107, 2108-2120.	3.5	53
4	Use of BTK inhibitors with special focus on ibrutinib in WaldenstrÃ¶m macroglobulinemia: An expert panel opinion statement. Hematological Oncology, 2022, 40, 332-340.	1.7	3
5	From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. Cancers, 2022, 14, 1562.	3.7	9
6	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. Hematological Oncology, 2022, 40, 518-527.	1.7	4
7	Ibrutinib dose intensity in highâ€risk chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 1100-1104.	1.7	1
8	Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. Hematological Oncology, 2022, 40, 1105-1108.	1.7	0
9	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Annals of Hematology, 2021, 100, 1733-1742.	1.8	10
10	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. Blood Advances, 2021, , .	5.2	14
11	Healthâ€related quality of life in Waldenstrom Macroglobulinemia and IgMâ€related disorders: A single institution experience. Hematological Oncology, 2020, 38, 111-113.	1.7	4
12	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	2.7	11
13	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	4.6	96
14	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WaldenstrÃ¶m macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	1.4	281
15	What is Fitness in the Era of Targeted Agents?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S84-S86.	0.4	3
16	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 2020, 105, e164-e168.	3.5	5
17	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory WaldenstrÃ¶m's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial. Blood, 2020, 136, 38-39.	1.4	7
18	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^{WT}) WaldenstrÃ¶m macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, e20056-e20056.	1.6	4

#	Article	IF	Citations
19	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	1.7	13
20	Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology, 2019, 12, 273-284.	2.2	3
21	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. Hematological Oncology, 2019, 37, 160-167.	1.7	15
22	Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. British Journal of Haematology, 2019, 186, 175-180.	2.5	9
23	Diagnostic framing of IgM monoclonal gammopathy: Focus on WaldenstrÃ¶m macroglobulinemia. Hematological Oncology, 2019, 37, 117-128.	1.7	15
24	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 2019, 133, 299-305.	1.4	69
25	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 43-56.	10.7	448
26	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	1.7	55
27	WALDENSTROMâ€™S MACROGLOBULINEMIA: AN UPDATE. Mediterranean Journal of Hematology and Infectious Diseases, 2018, 10, e2018004.	1.3	21
28	Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2018, 378, 2399-2410.	27.0	291
29	Singleâ€agent ibrutinib versus chemoimmunotherapy regimens for treatmentâ€naÃ¯ve patients with chronic lymphocytic leukemia: A crossâ€trial comparison of phase 3 studies. American Journal of Hematology, 2018, 93, 1402-1410.	4.1	24
30	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	3.5	111
31	Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2018, 36, 7502-7502.	1.6	21
32	Front-line treatment of CLL in the era of novel agents. Cancer Treatment Reviews, 2017, 53, 70-78.	7.7	25
33	Is HBV prophylaxis required during CLL treatment with ibrutinib?. Leukemia and Lymphoma, 2017, 58, 2966-2968.	1.3	14
34	Ibrutinib for patients with rituximab-refractory WaldenstrÃ¶m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	10.7	212
35	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	3.5	200
36	Long-Term Toxicity of Therapy in WaldenstrÃ¶m Macroglobulinemia. , 2017, , 357-365.		1

#	Article	IF	Citations
37	Central nervous system involvement by WaldenstrÃ¶m macroglobulinaemia (Bingâ€Neel syndrome): a multiâ€institutional retrospective study. British Journal of Haematology, 2016, 172, 709-715.	2.5	87
38	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica, 2016, 101, 1544-1552.	3.5	72
39	Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. Therapeutic Advances in Hematology, 2016, 7, 222-230.	2.5	2
40	Bing Neel Syndrome in a Previously Untreated Patient With WaldenstrÃ¶m's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e7-e9.	0.4	10
41	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
42	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Haematologica, 2015, 100, e501-e504.	3.5	22
43	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics: Targets and Therapy, 2015, 9, 75.	3.2	2
44	Bendamustine and rituximab combination is safe and effective as salvage regimen in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2015, 56, 2637-2642.	1.3	55
45	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2015, 373, 2425-2437.	27.0	1,261
46	Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era. Blood, 2015, 126, 5098-5098.	1.4	3
47	Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification. Blood, 2015, 126, 81-81.	1.4	44
48	Long Term Toxicity and Follow-up of WaldenstromÂ´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab. Blood, 2015, 126, 3958-3958.	1.4	0
49	Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. Blood, 2015, 126, 2686-2686.	1.4	12
50	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. Blood, 2015, 126, 5084-5084.	1.4	0
51	Overview on clinical trials in Waldenstrom's macroglobulinemia. Clinical Investigation, 2014, 4, 1139-1154.	0.0	0
52	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. Haematologica, 2014, 99, e159-e161.	3.5	4
53	Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. Blood, 2014, 124, 5654-5654.	1.4	13
54	Primary therapy of WaldenstrÃ¶m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, 122, 3276-3282.	1.4	180

#	Article	IF	Citations
55	Response assessment in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop. British Journal of Haematology, 2013, 160, 171-176.	2.5	226
56	Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 231-234.	0.4	24
57	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. Blood, 2013, 122, 1782-1782.	1.4	0
58	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. Cancer, 2012, 118, 434-443.	4.1	97
59	THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011031.	1.3	13
60	Comparison Between FISH and Immunostimulatory Oligonucleotide-Induced Metaphase Cytogenetics in Previously Untreated CLL: Impact on Prognosis. Blood, 2011, 118, 4587-4587.	1.4	0
61	The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy, 2010, 3, 227.	2.0	6
62	Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study. Blood, 2010, 116, 1384-1384.	1.4	0
63	Fludarabine-Based Combination Therapies for WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 67-70.	1.4	13
64	Positive Direct Antiglobulin Test (DAT) in Chronic Lymphocytic Leukemia (CLL) Patients: Correlation with Prognostic Factors.. Blood, 2009, 114, 2351-2351.	1.4	1
65	Clinical and Biological Implications of Hepatitis C Virus Positivity in Waldenstrom's Macroglobulinemia Patients.. Blood, 2009, 114, 2934-2934.	1.4	1
66	Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature. Leukemia Research, 2008, 32, 1221-1227.	0.8	81
67	Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstromâ€™s Macroglobulinemia. Blood, 2008, 112, 3692-3692.	1.4	1
68	Cryoglobulinemia. Blood Reviews, 2007, 21, 183-200.	5.7	137
69	High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemotherapy and Pharmacology, 2007, 59, 771-779.	2.3	13
70	Fludarabine, Cyclophosphamide and Rituximab in Waldenstroì¨mâ€™s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results. Blood, 2007, 110, 1290-1290.	1.4	7
71	Role of fludarabine in hematological malignancies. Expert Review of Anticancer Therapy, 2006, 6, 1141-1161.	2.4	21
72	Invasive aspergillosis in haematological malignancies: Clinical findings and management for intensive chemotherapy completion. American Journal of Hematology, 2001, 68, 231-236.	4.1	55